Like the earlier quarters, momentum for Injectables and Branded continued making up for the tough times being faced by Generics. Thankfully, the full-year guidance for Generics was maintained, after two downgrades this year. Overall, while the stock is down c.40% (in ytd terms) – mainly due to concerns around its Generics business, our positive recommendation is supported by the long-term growth potential of the biosimilar and generics markets, Hikma’s strong position in the target markets, and ....
04 Nov 2022
Q3 dynamics similar to prior periods, full-year guidance maintained
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 dynamics similar to prior periods, full-year guidance maintained
Hikma Pharmaceuticals Plc (HIK:LON) | 1,917 690.1 1.9% | Mkt Cap: 4,254m
- Published:
04 Nov 2022 -
Author:
Abhishek Raval -
Pages:
3
Like the earlier quarters, momentum for Injectables and Branded continued making up for the tough times being faced by Generics. Thankfully, the full-year guidance for Generics was maintained, after two downgrades this year. Overall, while the stock is down c.40% (in ytd terms) – mainly due to concerns around its Generics business, our positive recommendation is supported by the long-term growth potential of the biosimilar and generics markets, Hikma’s strong position in the target markets, and ....